NCT05995015View on ClinicalTrials.gov

4SCAR19U T Cells Targeting B Cell Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
B Cell Malignancies
Interventions
BIOLOGICAL

Universal CD19-specific CAR gene-engineered T cells

Infusion of 4SCAR19U cells

Trial Locations (1)

518000

RECRUITING

Shenzhen Geno-Immune Medical Institute, Shenzhen

All Listed Sponsors
lead

Shenzhen Geno-Immune Medical Institute

OTHER